Skip to main content

Table 2 Demographic and clinical characteristic of people living with HIV/AIDS diagnosed with TB at enrollment and during follow-up in the ClinSurv HIV Cohort, Germany 2001–2011

From: Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors

Characteristics

 

Female

Male

Total

  

N = 66 (28.3%)

N = 167 (71.7%)

N = 233 (100%)

Median age at enrollment (N = 232/1 missing data)

Median [IQR]

31 [26–45]

40 [32–47]

37 [30–45]

Median age at the time of TB diagnosis, years (N = 251/1 missing data)

Median [IQR]

32 [28–39]

40 [32–48]

37 [31–45]

Region of origin (N = 223/10 missing data)

N. (%)

   

   Germany

 

8 (12.5)

81 (50.9)

89 (39.9)

   Sub-Saharan Africa

 

41 (64.1)

41 (25.8)

82 (36.8)

   Other countries

 

15 (23.4)

37 (23.3)

52 (23.3)

HIV-transmission risk group (N = 214/19 missing data)

N. (%)

   

   MSM

 

---

67 (43.8)

67 (31.3)

   PWID

 

3 (4.9)

17 (11.1)

20 (9.4)

   HPC

 

54 (88.5)

43 (28.1)

97 (45.3)

   Others†

 

4 (6.6)

26 (16.9)

30 (14.0)

Median CD4+ blood cell count at enrollment (N = 221/12 missing data)

Median [IQR]

197 [67–349]

204 [67–375]

189 [66–348]

Median CD4+ blood cell count at the time of TB diagnosis (N = 194/39 missing data)

Median [IQR]

211 [65–339]

198 [47–339]

216 [69–350]

Median viral load at enrollment (log10copies/ml) (N = 210/23 missing data)

Median [IQR]

4.8 [3.6-5.4]

4.7 [3.4-5.5]

4.9 [3.6-5.3]

Median viral load at the time of TB diagnosis (N = 145/88 missing data)

Median [IQR]

5.0 [4.3-5.6]

5.2 [4.5-5.7]

5.9 [3.9-5.5]

Hepatitis B* (N = 233)

Median [IQR]

25 (37.9)

39 (23.4)

64 (27.5)

Hepatitis C* (N = 233)

Median [IQR]

5 (7.6)

18 (10.8)

23 (9.9)

Diabetes mellitus* (N = 233)

Median [IQR]

2 (3.0)

5 (3.0)

7 (3.0)

cART‡ (N = 233)

Median [IQR]

31 (50.0)

99 (59.3)

130 (55.8)

Died (N = 233)

N. (%)

4 (10.6)

18 (10.8)

25 (10.7)

  1. TB, tuberculosis; MSM, men who have sex with men; PWID, person who inject drugs; HPC, high HIV-prevalence countries; cART, combination antiretroviral therapy; IQR, interquartile range.
  2. *At any time during follow-up.
  3. †Others included heterosexual, blood transfusion and mother to child transmission.
  4. ‡cART initiated during follow-up at any time prior to TB diagnosis.